| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 26.59▲ | 26.62▼ | 26.63▼ | N/A | N/A |
| MA10 | 26.61▼ | 26.64▼ | N/A | N/A | N/A |
| MA20 | 26.63▼ | N/A | N/A | N/A | N/A |
| MA50 | 26.63▼ | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | N/A | N/A | N/A | N/A |
| RSI | 46.911▼ | N/A | N/A | N/A | N/A |
| STOCH | 26.190 | N/A | N/A | N/A | N/A |
| WILL %R | -66.667 | N/A | N/A | N/A | N/A |
| CCI | -85.490 | N/A | N/A | N/A | N/A |
|
Thursday, May 07, 2026 03:05 PM
Galapagos (NASDAQ:GLPG) executives used the company’s first-quarter 2026 earnings call to highlight what Chief Executive Officer Henry Gosebruch described as a “real transformation,” including ...
|
|
Wednesday, May 06, 2026 01:29 PM
Galapagos’ name change to Lakefront Biotherapeutics approved at the Company’s EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with ...
|
|
Wednesday, May 06, 2026 01:25 PM
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engag ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/05/26 | 26.60 | 26.74 | 26.42 | 26.61 | 175,043 |
| 18/05/26 | 26.88 | 26.95 | 26.42 | 26.69 | 211,944 |
|
|
||||
|
|
||||
|
|